Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical...
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that the company plans to explore the potential to develop a novel...
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth SolutionPatients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and Eversana™, an independent provider of global commercial services to the life science industry, today announced that Evoke,...
Zynex Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System
Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it has started enrollments in an ongoing apheresis...
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium...
e-Labeling Translations: IFU Localization for Global Markets
What makes e-labeling translations so important in the medical devices industry? With new frontiers in med device markets emerging globally, instructions for use (IFUs) are a requirement in most markets, which makes e-labeling translations for IFUs a necessary...
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the discovery, research, and development of new and effective treatments for psychiatric and neurological disorders, announced positive results from a preclinical...
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System...
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BeiGene and Novartis' unresectable hepatocellular carcinoma treatment is gaining ground as a potential treatment for advanced liver cancer. In the Phase III RATIONALE 301 trial of Tislelizumab as a first-line treatment, the drug met its primary endpoint of...
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com